Lin M, Paik E, Mishra B, et al. Re-creating hereditary persistence of fetal hemoglobin (PHFH) with CRISPR/CAS9 to treat sickle cell disease (SCD) and beta-thalassemia (beta-thal). EHA 2017, abstract S147.
Advies: uitbreiding vergoeding axicabtagene ciloleucel (Yescarta) voor behandeling lymfeklierkanker
jun 2024 | Lymfoom